Normal infant by a gestational carrier for a phenylketonuria mother: alternative therapy

Robert O Fisch1, Jacques P Stassart

  • 1Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA. fisch001@umn.edu

Insights

Pregnancies in untreated phenylketonuria (PKU) mothers pose risks to fetal development. A successful term pregnancy using a gestational carrier offered a healthy infant to an untreated PKU mother, presenting a new option.

Area of Science:

  • Reproductive Medicine
  • Metabolic Disorders
  • Genetics

Background:

  • Untreated phenylketonuria (PKU) in mothers leads to severe fetal complications, including miscarriage, growth restriction, and developmental issues.
  • These abnormalities are attributed to the intrauterine environment, not genetic factors, as PKU fathers have normal children.
  • Maternal dietary control before and during pregnancy is crucial but not always effective in preventing fetal complications.

Observation:

  • A 26-year-old fertile woman with PKU underwent controlled ovarian stimulation and IVF.
  • Her oocytes were fertilized with her husband's sperm, and two embryos were transferred to a gestational carrier.
  • The gestational carrier had a successful term pregnancy, delivering a healthy male infant without abnormalities.

Findings:

  • The infant born to the untreated PKU mother via gestational carrier was normal at birth and at one year of age.
  • This represents the first reported successful term pregnancy in an untreated PKU mother using a gestational carrier.
  • The infant exhibited normal growth and developmental assessments.

Implications:

  • Gestational carrier surrogacy offers a viable alternative for women with PKU unable or unwilling to adhere to strict dietary management.
  • This approach can help prevent the adverse intrauterine environmental effects of maternal PKU on fetal development.
  • It provides a pathway to healthy offspring for PKU patients, improving reproductive outcomes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...